William D. Chey

ORCID: 0000-0002-4584-4026 · 4 papers in corpus
rct 2022
Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial
Neurogastroenterology and motility ·doi:10.1111/nmo.14448

BACKGROUND: Preclinical and clinical studies suggest that β3 -adrenergic receptor activation may be a novel target for treating abdominal pain and gastrointestinal motility dysfunction in patients with irritable bowel syndrome (IBS). This p…

observational 2020
Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: Results of a Nationwide Population-Based Study
The American journal of gastroenterology ·doi:10.14309/ajg.0000000000000502

INTRODUCTION: Abdominal pain is a cardinal feature of irritable bowel syndrome (IBS); however, differences in abdominal pain among IBS subtypes remain unknown. We aimed to characterize abdominal pain symptoms among established IBS subtypes …

observational 2020
Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms
Gastroenterology ·doi:10.1053/j.gastro.2019.12.014

BACKGROUND & AIMS: There are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United States. We performed a population-based study to determine the prevalence of GERD symptoms and persistent GERD symptoms despite …

observational 2018
Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans
The American journal of gastroenterology ·doi:10.1038/s41395-018-0256-8

OBJECTIVES: Digestive diseases account for >100 million ambulatory care visits annually in the U.S. Yet, comparatively less is known about the true burden of gastrointestinal (GI) symptoms in the general U.S. POPULATION: The aim of this st…